Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DGAT1 | O75907 | 9/20 | 0.32 |
| ▸ | SOAT1 | P35610 | 5/20 | 0.32 |
| ▸ | HDAC4 | P56524 | 2/20 | 0.32 |
| ▸ | FAAH | O00519 | 1/20 | 0.32 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.32 |
| ▸ | DGAT2 | Q96PD7 | 1/20 | 0.32 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.32 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | SLC2A1 | P11166 | 2/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1003346 | 0.78 | HCRTR2 (0.38) | DGAT1 | |
| SCHEMBL15766917 | 0.73 | KDM1A (0.51) | HDAC4ALDH1A1 | |
| SCHEMBL1000359 | 0.73 | KDM1A (0.51) | HDAC4ALDH1A1 | |
| SCHEMBL15766918 | 0.73 | KDM1A (0.51) | HDAC4ALDH1A1 | |
| SCHEMBL3267276 | 0.73 | RXRA (0.49) | HDAC4PDE10ACYP2C9 | |
| SCHEMBL1003112 | 0.72 | MAPT (0.36) | DGAT1SOAT1FAAHCHRM2DGAT2 | |
| SCHEMBL9820886 | 0.71 | KDM1A (0.35) | CYP2C9 | |
| SCHEMBL11700667 | 0.69 | KDM1A (0.51) | — | |
| SCHEMBL15767640 | 0.69 | KDM1A (0.51) | — | |
| SCHEMBL1943935 | 0.69 | KDM1A (0.51) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2011094209-A1 | PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF PAIN AND OTHER INDICATONS | MERCK SHARP & DOHME CORP. (US) | 2011-08-04 | — | — | WO | disclosed |
| US-20110144119-A1 | OXAZOLE DERIVATIVES USEFUL AS INHIBITORS OF FAAH | MERCK SHARP & DOHME LLC | 2011-06-16 | — | — | US | disclosed |
| US-20110021531-A1 | OXAZOLE DERIVATIVES USEFUL AS INHIBITORS OF FAAH | MERCK SHARP & DOHME CORP. | 2011-01-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110144119-A1 | OXAZOLE DERIVATIVES USEFUL AS INHIBITORS OF FAAH | FAAH, FAAH2, ALOX5 | DGAT1 563/4885SOAT1 690/4885HDAC4 352/4885 |
| US-20110021531-A1 | OXAZOLE DERIVATIVES USEFUL AS INHIBITORS OF FAAH | FAAH, FAAH2, ALOX5 | DGAT1 408/4885SOAT1 432/4885HDAC4 418/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.